Abstract:BackgroundSteroids are a leading cause of femoral head osteonecrosis. Currently there are no medications available to prevent and/or treat steroid-associated osteonecrosis. Low-intensity pulsed ultrasound (LIPUS) was approved by the FDA for treating delayed union of bone fractures. Some studies have reported that LIPUS can enhance bone formation and local blood flow in an animal model of fracture healing. However, whether the effect of osteogenesis and neovascularization by LIPUS can enhance the repair progress in steroid-associated osteonecrosis is unknown.Questions/purposesWe hypothesized that LIPUS may facilitate osteogenesis and neovascularization in the reparative processes of steroid-associated osteonecrosis. Using a rabbit animal model, we asked whether LIPUS affects (1) bone strength and trabecular architecture; (2) blood vessel number and diameter; and (3) BMP-2 and VEGF expression.MethodsBilateral femoral head necrosis was induced by lipopolysaccharide and methylprednisolone in 24 rabbits. The left femoral heads of rabbits received LIPUS therapy (200 mW/cm2) for 20 minutes daily and were classified as the LIPUS group. The right femoral heads of the same rabbits did not receive therapy and were classified as the control group. All rabbits were euthanized 12 weeks after LIPUS therapy. Micro-CT, biomechanical testing, histologic evaluation, immunohistochemistry, quantitative real-time PCR, and Western blot were used for examination of the effects of LIPUS.ResultsTwelve weeks after LIPUS treatment, the loading strength in the control group was 355 ± 38 N (95% CI, 315–394 N), which was lower (p = 0.028) than that in the LIPUS group (441 ± 78 N; 95% CI, 359–524 N). The bone tissue volume density (bone volume/total volume) in the LIPUS group (49.29% ± 12.37%; 95 % CI, 36.31%–62.27%) was higher (p = 0.022) than that in the control group (37.93% ± 8.37%; 95 % CI, 29.15%–46.72%). The percentage of empty osteocyte lacunae in the LIPUS group (17% ± 4%; 95% CI, 15%–20%) was lower (p = 0.002) than that in the control group (26% ± 9%; 95% CI, 21%–32%). The mineral apposition rate (μm/day) in the LIPUS group (2.3 ± 0.8 μm/day; 95% CI, 1.8 2.8 μm/day) was higher (p = 0.001) than that in the control group (1.6 ± 0.3 μm/day; 95% CL, 1.4–1.8 μm/day). The number of blood vessels in the LIPUS group (7.8 ± 3.6/mm2; 95% CI, 5.5–10.1 mm2) was greater (p = 0.025) than the number in the control group (5.7 ± 2.6/mm2; 95% CI, 4.0–7.3 mm2). Messenger RNA (mRNA) and protein expression of BMP-2 in the LIPUS group (75 ± 7, 95% CI, 70–79; and 30 ± 3, 95% CI, 28–31) were higher (both p < 0.001) than those in the control groups (46 ± 5, 95% CI, 43–49; and 15 ± 2, 95% CI, 14–16). However, there were no differences (p = 0.114 and 0.124) in mRNA and protein expression of vascular endothelial growth factor between the control (26 ± 3, 95% CI, 24–28; and 22 ± 6, 95% CI, 18–26) and LIPUS groups (28 ± 2, 95% CI, 26–29; and 23 ± 6, 95% CI, 19–27).ConclusionsThe results of this study indicate that LIPUS promotes osteogenesis and neovascularization, thus promoting bone repair in this steroid-associated osteonecrosis model.Clinical RelevanceLIPUS may be a promising modality for the treatment of early-stage steroid-associated osteonecrosis. Further research, including clinical trials to determine whether LIPUS has a therapeutic effect on patients with early-onset steroid-associated osteonecrosis may be warranted.

BADGE, a synthetic antagonist for PPARγ, prevents steroid-related osteonecrosis in a rabbit model

Inhibition of PPARγ by bisphenol A diglycidyl ether ameliorates dexamethasone-induced osteoporosis in a mouse model

Preventive effects of siRNA targeting PPARγ gene on steroid-induced osteonecrosis in rabbits

Beneficial Effect of Grape Seed Proanthocyanidin Extract in Rabbits with Steroid-Induced Osteonecrosis Via Protecting Against Oxidative Stress and Apoptosis.

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Prevents Steroid-Associated Osteonecrosis of the Femoral Head in Rabbits by Promoting Angiogenesis and Inhibiting Apoptosis

Construction of the model of steroid-induced osteonecrosis in rabbits and exploration of the pathogenesis of the osteonecrosis femoral head

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

PTH[1-34] Improves the Effects of Core Decompression in Early-Stage Steroid-Associated Osteonecrosis Model by Enhancing Bone Repair and Revascularization

Edaravone, a Novel Free Radical Scavenger, Prevents Steroid-Induced Osteonecrosis in Rabbits.

Nirogacestat Suppresses RANKL-Induced Osteoclast Formation in Vitro and Attenuates LPS-Induced Bone Resorption in Vivo.

Investigation on the Role on Perindopril for Prevention and Treatment of Glucocorticoid Induced Osteoporosis in Rab-Bits

Genes expressions of PPARγ and BMP2 inside the femoral head of steroid-induced osteonecrosis in rabbits

P‐glycoprotein Overexpression in Bone Marrow–derived Multipotent Stromal Cells Decreases the Risk of Steroid‐induced Osteonecrosis in the Femoral Head

Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models

Role of the Local Bone Renin-Angiotensin System in Steroid-Induced Osteonecrosis in Rabbits

The Effects of P-gp and CYP450 Modulated by Rifampicin on the Steroid-Induced Osteonecrosis of the Femoral Head

Gastrodin prevents steroid-induced osteonecrosis of the femoral head in rats by anti-apoptosis

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss

Unveiling the potential of Butylphthalide: inhibiting osteoclastogenesis and preventing bone loss

Low-intensity Pulsed Ultrasound Enhances Bone Repair in a Rabbit Model of Steroid-associated Osteonecrosis